{"protocolSection":{"identificationModule":{"nctId":"NCT00258154","orgStudyIdInfo":{"id":"V260-010"},"secondaryIdInfos":[{"id":"2005_046"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010)","officialTitle":"Safety and Immunogenicity of Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants"},"statusModule":{"statusVerifiedDate":"2015-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-02"},"primaryCompletionDateStruct":{"date":"2006-11","type":"ACTUAL"},"completionDateStruct":{"date":"2006-11","type":"ACTUAL"},"studyFirstSubmitDate":"2005-11-15","studyFirstSubmitQcDate":"2005-11-22","studyFirstPostDateStruct":{"date":"2005-11-24","type":"ESTIMATED"},"resultsFirstSubmitDate":"2009-08-10","resultsFirstSubmitQcDate":"2009-08-10","resultsFirstPostDateStruct":{"date":"2009-09-23","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-10-05","lastUpdatePostDateStruct":{"date":"2015-10-06","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"The study is being conducted to demonstrate that the vaccine to prevent gastroenteritis due to rotavirus may be administered concomitantly with INFANRIX(tm)hexa without impairing the safety and immunogenicity of either vaccine."},"conditionsModule":{"conditions":["Rotavirus Disease"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":403,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","description":"RotaTeq/Infanrix Hexa","interventionNames":["Biological: Rotavirus Vaccine, Live, Oral, Pentavalent","Biological: Comparator: Infanrix(tm) Hexa"]},{"label":"2","type":"PLACEBO_COMPARATOR","description":"Placebo/Infanrix Hexa","interventionNames":["Biological: Comparator: placebo","Biological: Comparator: Infanrix(tm) Hexa"]}],"interventions":[{"type":"BIOLOGICAL","name":"Rotavirus Vaccine, Live, Oral, Pentavalent","description":"3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2","armGroupLabels":["1"]},{"type":"BIOLOGICAL","name":"Comparator: placebo","description":"3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2","armGroupLabels":["2"]},{"type":"BIOLOGICAL","name":"Comparator: Infanrix(tm) Hexa","description":"3 doses of oral Infanrix(tm) Hexa on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2","armGroupLabels":["1","2"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Immunogenicity of INFANRIX™ Hexa in Relation to Anti-hepatitis B Surface Antigen HBsAg, Predose 1","description":"Geometric Mean Titer (GMT)/antibody responses to RotaTeq™ and INFANRIX™ in relation to anti-hepatitis B surface antigen HBsAg at start of a 3-dose regimen","timeFrame":"Day 1 of a 3-dose regimen"},{"measure":"Immunogenicity of INFANRIX™ Hexa in Relation to Anti-hepatitis B Surface Antigen HBsAg , at 42 Days After a 3-dose Regimen","description":"GMT/antibody responses to RotaTeq™ and INFANRIX™ in relation to anti-hepatitis B surface antigen HBsAg at 42 days after 3-dose regimen","timeFrame":"42 days after 3-dose regimen"},{"measure":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Anti-polyribosylribitol Phosphate PRP, Predose 1","description":"GMT/antibody responses to RotaTeq™ and INFANRIX™ hexa in relation to serum anti-polyribosylribitol phosphate PRP at start of 3-dose regimen","timeFrame":"Day 1 of 3-dose regimen"},{"measure":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Anti-polyribosylribitol Phosphate PRP at 42 Days After a 3-dose Regimen","description":"GMT/antibody responses to RotaTeq™ and INFANRIX™ hexa in relation to serum anti-polyribosylribitol phosphate PRP at 42 days after a 3-dose regimen","timeFrame":"42 days after a 3-dose regimen"}],"secondaryOutcomes":[{"measure":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 1 When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of Poliovirus Type 1 in subjects with even allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","timeFrame":"Predose (Day 1 of a 3-dose regimen)"},{"measure":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 1 When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of Poliovirus Type 1 in subjects with even allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa , 42 days after a 3-dose regimen","timeFrame":"42 days after a 3-dose regimen"},{"measure":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 2 When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of Poliovirus Type 2 in subjects with even allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","timeFrame":"Pre-dose (Day 1 of a 3-dose regimen)"},{"measure":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 2 When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of Poliovirus Type 2 in subjects with even allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","timeFrame":"42 days after in a 3-dose regimen"},{"measure":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 3 When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of Poliovirus Type 3 in subjects with even allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","timeFrame":"Predose (Day 1 of a 3-dose regimen)"},{"measure":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 3 When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of Poliovirus Type 3 in subjects with even allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","timeFrame":"42 days after a 3-dose regimen"},{"measure":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Diphtheria Toxoid When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of diphtheria toxoid in subjects with odd allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","timeFrame":"Predose (Day 1 of a 3-dose regimen)"},{"measure":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Diphtheria Toxoid When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of diphtheria toxoid in subjects with odd allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","timeFrame":"42 days after a 3-dose regimen"},{"measure":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Tetanus Toxoid When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of tetanus toxoid in subjects with odd allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","timeFrame":"Predose (Day 1 of a 3-dose regimen)"},{"measure":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Tetanus Toxoid When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of tetanus toxoid in subjects with odd allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","timeFrame":"42 days after a 3-dose regimen"},{"measure":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis FHA When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of pertussis FHA in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","timeFrame":"Predose (Day 1 of a 3-dose regimen)"},{"measure":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis FHA When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of pertussis FHA in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","timeFrame":"42 days after a 3-dose regimen"},{"measure":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis Pertactin When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of pertussis Pertactin in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","timeFrame":"Predose (Day 1 of a 3-dose regimen)"},{"measure":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis Pertactin When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of pertussis Pertactin in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","timeFrame":"42 days after a 3-dose regimen"},{"measure":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis Toxoid When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of pertussis toxoid in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","timeFrame":"Predose (Day 1 of a 3-dose regimen)"},{"measure":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis Toxoid When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of pertussis toxoid in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","timeFrame":"42 days after a 3-dose regimen"},{"measure":"Serum Neutralizing Antibody (SNA) Response to Serotype G1 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa, Predose 1","description":"GMT of serotype G1 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","timeFrame":"Predose (Day 1 of a 3-dose regimen)"},{"measure":"Serum Neutralizing Antibody (SNA) Response to Serotype G1 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa, 42 Days After a 3-dose Regimen","description":"GMT of serotype G1 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","timeFrame":"42 days after a 3-dose regimen"},{"measure":"Serum Neutralizing Antibody (SNA) Response to Serotype G2 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa, Predose 1","description":"GMT of serotype G2 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","timeFrame":"Predose (Day 1 of a 3-dose regimen)"},{"measure":"Serum Neutralizing Antibody (SNA) Response to Serotype G2 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa 42 Days After a 3-dose Regimen","description":"GMT of serotype G2 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","timeFrame":"42 days after a 3-dose regimen"},{"measure":"Serum Neutralizing Antibody (SNA) Response to Serotype G3 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa Predose 1","description":"GMT of serotype G3 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa Predose 1","timeFrame":"Predose (Day 1 of a 3-dose regimen)"},{"measure":"Serum Neutralizing Antibody (SNA) Response to Serotype G3 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa 42 Days After a 3-dose Regimen","description":"GMT of serotype G3 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","timeFrame":"42 days after a 3-dose regimen"},{"measure":"Serum Neutralizing Antibody (SNA) Response to Serotype G4 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa Predose 1","description":"GMT of serotype G4 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa Predose 1","timeFrame":"Predose (Day 1 of a 3-dose regimen)"},{"measure":"Serum Neutralizing Antibody (SNA) Response to Serotype G4 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa 42 Days After a 3-dose Regimen","description":"GMT of serotype G4 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","timeFrame":"42 days after a 3-dose regimen"},{"measure":"Serum Neutralizing Antibody (SNA) Response to Serotype P1A in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa Predose 1","description":"GMT of serotype P1A in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa Predose 1","timeFrame":"Predose (Day 1 of a 3-dose regimen)"},{"measure":"Serum Neutralizing Antibody (SNA) Response to Serotype P1A in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa 42 Days After a 3-dose Regimen","description":"GMT of serotype P1A in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","timeFrame":"42 days after a 3-dose regimen"},{"measure":"Serum Neutralizing Antibody (SNA) Response to Serum Anti-rotavirus IgA in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa Predose 1","description":"GMT of serum anti-rotavirus IgA in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa Predose 1","timeFrame":"Predose (Day 1 of a 3-dose regimen)"},{"measure":"Serum Neutralizing Antibody (SNA) Response to Serum Anti-rotavirus IgA in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa 42 Days After a 3-dose Regimen","description":"GMT of serum anti-rotavirus IgA in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","timeFrame":"42 days after a 3-dose regimen"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy infant per investigator, 6 through 12 weeks of age\n\nExclusion Criteria:\n\n* History of congenital abdominal disorders, intussusception, or abdominal surgery\n* Known or suspected impairment of immunological function\n* Known hypersensitivity to any component of the rotavirus vaccine\n* Prior administration of any rotavirus vaccine\n* Known hypersensitivity or contraindication to any component of INFANRIX(tm) hexa\n* Any infant born from a known HBsAg-positive mother\n* Prior administration of any oral polio vaccine\n* Receipt of one or more doses of inactivated poliovirus vaccine, diptheria, tetanus and acellular pertussis vaccine, diptheria, tetanus and pertussis vaccine, Haemophilus influenzae type b vaccine, or any hepatitis B vaccine prior to the first vaccination, or receipt of any vaccines with these antigens at any time during the course of the study\n* Fever, with a rectal temperature greater than or equal to 38.1 degree C (greater than or equal to 100.5 degree F) at the time of immunization\n* History of known prior rotavirus gastroenteritis, chronic diarrhea, or failure to thrive\n* Clinical evidence of active gastrointestinal illness\n* Receipt of intramuscular, oral, or intravenous corticosteroid treatment within the 2 weeks prior to vaccination\n* Infants residing in a household with an immunocompromised person\n* Prior receipt of a blood transfusion or blood products\n* Participation in another clinical study within 42 days before the beginning or anytime during the duration of the current clinical study\n* Any infant who cannot be adequately followed for safety by a contact visit\n* History of seizure disorders or prior history followed for safety by a contact visit\n* Any condition that, in the opinion of the investigator, may interfere with the evaluation of the study objectives","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Weeks","maximumAge":"12 Weeks","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Monitor","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}]},"referencesModule":{"references":[{"pmid":"19209092","type":"RESULT","citation":"Ciarlet M, He S, Lai S, Petrecz M, Yuan G, Liu GF, Mikviman E, Heaton PM, Panzer F, Rose T, Koller DY, Van Damme P, Schodel F. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Pediatr Infect Dis J. 2009 Mar;28(3):177-81. doi: 10.1097/INF.0b013e31818c0161."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Excluded from randomization were patients with history of congenital abdominal disorders, intussusception, or abdominal surgery; history of known prior rotavirus disease, chronic diarrhea, or failure to thrive, clinical evidence of active gastrointestinal illness and those with fever, a rectal temperature \\>38.1°C (\\>100.5°F) at time of immunization.","recruitmentDetails":"Enrollment occurred at 26 sites in Austria, Belgium, and Germany from 22Feb2006 (first subject in) to 13Nov2006 (last subject out). Cutoff date for all clinical and laboratory data from the Case Report Forms in-house was 08Jun2007. Access to the clinical database was granted on 15Jun2007.","groups":[{"id":"FG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"FG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Healthy infants who started in the RotaTeq™ concomitantly with INFANRIX™ hexa group.","numSubjects":"201"},{"groupId":"FG001","comment":"Healthy infants who started in the Placebo concomitantly with INFANRIX™ hexa group.","numSubjects":"202"}]},{"type":"Vaccinated at Visit 1","achievements":[{"groupId":"FG000","numSubjects":"201"},{"groupId":"FG001","numSubjects":"202"}]},{"type":"Vaccinated at Visit 2","achievements":[{"groupId":"FG000","numSubjects":"198"},{"groupId":"FG001","numSubjects":"198"}]},{"type":"Vaccinated at Visit 3","achievements":[{"groupId":"FG000","numSubjects":"195"},{"groupId":"FG001","numSubjects":"197"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"Subjects who completed the study.","numSubjects":"192"},{"groupId":"FG001","comment":"Subjects who completed the study.","numSubjects":"195"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"7"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Patient Moved","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"BG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"201"},{"groupId":"BG001","value":"202"},{"groupId":"BG002","value":"403"}]}],"measures":[{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"5 Weeks of Age and Under","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]},{"title":"6-12 Weeks of Age","categories":[{"measurements":[{"groupId":"BG000","value":"199"},{"groupId":"BG001","value":"202"},{"groupId":"BG002","value":"401"}]}]},{"title":"Over 12 Weeks of Age","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"104"},{"groupId":"BG001","value":"102"},{"groupId":"BG002","value":"206"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"97"},{"groupId":"BG001","value":"100"},{"groupId":"BG002","value":"197"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"}]}]},{"title":"Black","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"21"}]}]},{"title":"Multi-Racial","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"186"},{"groupId":"BG001","value":"187"},{"groupId":"BG002","value":"373"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Anti-hepatitis B Surface Antigen HBsAg, Predose 1","description":"Geometric Mean Titer (GMT)/antibody responses to RotaTeq™ and INFANRIX™ in relation to anti-hepatitis B surface antigen HBsAg at start of a 3-dose regimen","populationDescription":"All per-protocol subjects were included in the analysis of primary endpoints for polyribosylribitol phosphate (PRP) and hepatitis B surface antigen (HBsAg). Subjects listed in the Protocol Violation Memo were excluded from the immunogenicity analysis; N analyzed = number of subjects contributing to per protocol analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"mIU/mL","timeFrame":"Day 1 of a 3-dose regimen","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"184"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7","lowerLimit":"10.0","upperLimit":"16.1"},{"groupId":"OG001","value":"13.5","lowerLimit":"10.5","upperLimit":"17.4"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 1 When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of Poliovirus Type 1 in subjects with even allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","populationDescription":"Per Protocol Analysis on Subset A (subjects with even allocation numbers)","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Dilution Unit","timeFrame":"Predose (Day 1 of a 3-dose regimen)","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","lowerLimit":"11.3","upperLimit":"20.2"},{"groupId":"OG001","value":"18.3","lowerLimit":"12.9","upperLimit":"26.0"}]}]}]},{"type":"PRIMARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Anti-hepatitis B Surface Antigen HBsAg , at 42 Days After a 3-dose Regimen","description":"GMT/antibody responses to RotaTeq™ and INFANRIX™ in relation to anti-hepatitis B surface antigen HBsAg at 42 days after 3-dose regimen","populationDescription":"All per-protocol subjects were included in the analysis of primary endpoints for polyribosylribitol phosphate (PRP) and hepatitis B surface antigen (HBsAg). Subjects listed in the Protocol Violation Memo were excluded from the immunogenicity analysis; N analyzed = number of subjects contributing to per protocol analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"mIU/mL","timeFrame":"42 days after 3-dose regimen","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"184"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"227.8","lowerLimit":"189.2","upperLimit":"274.2"},{"groupId":"OG001","value":"261.0","lowerLimit":"219.3","upperLimit":"310.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"non-inferiority criterion is that the lower limit of the 2-sided 95% confidence interval of the proportion difference (Rotateq+INFANRIX hexa group minus Placebo+INFANRIX hexa group) for subjects who achieve serum antibody levels of ≥ 10 mIU/mL greater than -10%","pValue":"<0.001","statisticalMethod":"Miettinen and Nurminen's","statisticalComment":"Comparing percentage difference with the non-inferiority margin of 10 percentage point with Miettinen and Nurminen's method","paramType":"Percentage point difference","paramValue":"0.0","ciPctValue":"95","ciLowerLimit":"-3.7","ciUpperLimit":"3.6","estimateComment":"Percentage point difference (RotaTeq - Placebo)"}]},{"type":"PRIMARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Anti-polyribosylribitol Phosphate PRP, Predose 1","description":"GMT/antibody responses to RotaTeq™ and INFANRIX™ hexa in relation to serum anti-polyribosylribitol phosphate PRP at start of 3-dose regimen","populationDescription":"All per-protocol subjects were included in the analysis of primary endpoints for polyribosylribitol phosphate (PRP) and hepatitis B surface antigen (HBsAg). Subjects listed in the Protocol Violation Memo were excluded from the immunogenicity analysis; N analyzed = number of subjects contributing to per protocol analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ng/mL","timeFrame":"Day 1 of 3-dose regimen","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"184"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"204.3","lowerLimit":"181.6","upperLimit":"229.8"},{"groupId":"OG001","value":"189.7","lowerLimit":"170.0","upperLimit":"211.8"}]}]}]},{"type":"PRIMARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Anti-polyribosylribitol Phosphate PRP at 42 Days After a 3-dose Regimen","description":"GMT/antibody responses to RotaTeq™ and INFANRIX™ hexa in relation to serum anti-polyribosylribitol phosphate PRP at 42 days after a 3-dose regimen","populationDescription":"All per-protocol subjects were included in the analysis of primary endpoints for polyribosylribitol phosphate (PRP) and hepatitis B surface antigen (HBsAg). Subjects listed in the Protocol Violation Memo were excluded from the immunogenicity analysis; N analyzed = number of subjects contributing to per protocol analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ng/mL","timeFrame":"42 days after a 3-dose regimen","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"184"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1316","lowerLimit":"1081","upperLimit":"1603"},{"groupId":"OG001","value":"1400","lowerLimit":"1172","upperLimit":"1672"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"non-inferiority criterion is that the lower limit of the 2-sided 95% confidence interval of the proportion difference (Rotateq+INFANRIX hexa group minus Placebo+INFANRIX hexa group) for subjects who achieve serum antibody levels of ≥ 0.15 μg/mL greater than -10%.","pValue":"0.015","statisticalMethod":"Miettinen and Nurminen's","statisticalComment":"Comparing percentage difference with the non-inferiority margin of 10 percentage point with Miettinen and Nurminen's method","paramType":"Percentage point difference","paramValue":"-3.7","ciPctValue":"95","ciLowerLimit":"-9.3","ciUpperLimit":"1.3","estimateComment":"Percentage point difference (RotaTeq - Placebo)"}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 1 When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of Poliovirus Type 1 in subjects with even allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa , 42 days after a 3-dose regimen","populationDescription":"Per Protocol Analysis on Subset A (subjects with even allocation numbers)","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Dilution Unit","timeFrame":"42 days after a 3-dose regimen","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.9","lowerLimit":"68.9","upperLimit":"130.6"},{"groupId":"OG001","value":"160.2","lowerLimit":"113.6","upperLimit":"225.8"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 2 When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of Poliovirus Type 2 in subjects with even allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","populationDescription":"Per Protocol Analysis on Subset A (subjects with even allocation numbers)","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Dilution Unit","timeFrame":"Pre-dose (Day 1 of a 3-dose regimen)","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","lowerLimit":"9.8","upperLimit":"16.8"},{"groupId":"OG001","value":"12.7","lowerLimit":"9.2","upperLimit":"17.6"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 2 When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of Poliovirus Type 2 in subjects with even allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","populationDescription":"Per Protocol Analysis on Subset A (subjects with even allocation numbers)","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Dilution Unit","timeFrame":"42 days after in a 3-dose regimen","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.1","lowerLimit":"45.8","upperLimit":"86.8"},{"groupId":"OG001","value":"69.4","lowerLimit":"48.6","upperLimit":"99.2"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 3 When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of Poliovirus Type 3 in subjects with even allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","populationDescription":"Per Protocol Analysis on Subset A (subjects with even allocation numbers)","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Dilution Unit","timeFrame":"Predose (Day 1 of a 3-dose regimen)","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","lowerLimit":"6.8","upperLimit":"12.1"},{"groupId":"OG001","value":"7.8","lowerLimit":"5.7","upperLimit":"10.7"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 3 When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of Poliovirus Type 3 in subjects with even allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","populationDescription":"Per Protocol Analysis on Subset A (subjects with even allocation numbers)","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Dilution Unit","timeFrame":"42 days after a 3-dose regimen","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"222.9","lowerLimit":"153.9","upperLimit":"322.8"},{"groupId":"OG001","value":"263.9","lowerLimit":"173.5","upperLimit":"401.5"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Diphtheria Toxoid When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of diphtheria toxoid in subjects with odd allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","populationDescription":"Per Protocol Analysis on Subset B (subjects with odd allocation number)","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"IU/mL","timeFrame":"Predose (Day 1 of a 3-dose regimen)","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"104"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.1"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Diphtheria Toxoid When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of diphtheria toxoid in subjects with odd allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","populationDescription":"Per Protocol Analysis on Subset B (subjects with odd allocation number)","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"IU/mL","timeFrame":"42 days after a 3-dose regimen","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.1","upperLimit":"0.1"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.1","upperLimit":"0.1"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Tetanus Toxoid When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of tetanus toxoid in subjects with odd allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","populationDescription":"Per Protocol Analysis on Subset B (subjects with odd allocation numbers)","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"IU/mL","timeFrame":"Predose (Day 1 of a 3-dose regimen)","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"104"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.2","upperLimit":"0.4"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.2","upperLimit":"0.5"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Tetanus Toxoid When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of tetanus toxoid in subjects with odd allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","populationDescription":"Per Protocol Analysis on Subset B (subjects with odd allocation numbers","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Dilution Unit","timeFrame":"42 days after a 3-dose regimen","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"101"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","lowerLimit":"1.1","upperLimit":"1.7"},{"groupId":"OG001","value":"1.5","lowerLimit":"1.2","upperLimit":"1.8"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis FHA When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of pertussis FHA in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","populationDescription":"Per Protocol Analysis","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EU/mL","timeFrame":"Predose (Day 1 of a 3-dose regimen)","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"177"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","lowerLimit":"3.2","upperLimit":"5.9"},{"groupId":"OG001","value":"3.7","lowerLimit":"2.7","upperLimit":"5.1"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis FHA When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of pertussis FHA in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","populationDescription":"Per Protocol Analysis","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EU/mL","timeFrame":"42 days after a 3-dose regimen","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"176"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","lowerLimit":"67.2","upperLimit":"81.4"},{"groupId":"OG001","value":"78.8","lowerLimit":"71.6","upperLimit":"86.7"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis Pertactin When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of pertussis Pertactin in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","populationDescription":"Per Protocol Analysis","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EU/mL","timeFrame":"Predose (Day 1 of a 3-dose regimen)","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"177"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.7","upperLimit":"1.4"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.7","upperLimit":"1.4"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis Pertactin When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of pertussis Pertactin in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","populationDescription":"Per Protocol Analysis","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EU/mL","timeFrame":"42 days after a 3-dose regimen","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"177"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109.6","lowerLimit":"96.7","upperLimit":"124.1"},{"groupId":"OG001","value":"108.2","lowerLimit":"93.5","upperLimit":"125.1"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis Toxoid When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of pertussis toxoid in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","populationDescription":"Per Protocol Analysis","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EU/mL","timeFrame":"Predose (Day 1 of a 3-dose regimen)","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"177"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.2","upperLimit":"0.2"},{"groupId":"OG001","value":"0.2","lowerLimit":"0.2","upperLimit":"0.3"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis Toxoid When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of pertussis toxoid in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","populationDescription":"Per Protocol Analysis","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EU/mL","timeFrame":"42 days after a 3-dose regimen","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"176"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","lowerLimit":"24.8","upperLimit":"31.7"},{"groupId":"OG001","value":"28.3","lowerLimit":"25.2","upperLimit":"31.8"}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serotype G1 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa, Predose 1","description":"GMT of serotype G1 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","populationDescription":"Per Protocol Analysis","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"GMT","timeFrame":"Predose (Day 1 of a 3-dose regimen)","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"182"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","lowerLimit":"19.6","upperLimit":"27.7"},{"groupId":"OG001","value":"24","lowerLimit":"20.3","upperLimit":"28.4"}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serotype G1 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa, 42 Days After a 3-dose Regimen","description":"GMT of serotype G1 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","populationDescription":"Per Protocol Analysis","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"GMT","timeFrame":"42 days after a 3-dose regimen","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"183"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"115.7","lowerLimit":"94.2","upperLimit":"142.1"},{"groupId":"OG001","value":"8.2","lowerLimit":"7.2","upperLimit":"9.3"}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serotype G2 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa, Predose 1","description":"GMT of serotype G2 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","populationDescription":"Per Protocol Analysis","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"GMT","timeFrame":"Predose (Day 1 of a 3-dose regimen)","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"181"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","lowerLimit":"10.2","upperLimit":"13.4"},{"groupId":"OG001","value":"12.2","lowerLimit":"10.6","upperLimit":"14.1"}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serotype G2 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa 42 Days After a 3-dose Regimen","description":"GMT of serotype G2 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","populationDescription":"Per Protocol Analysis","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"GMT","timeFrame":"42 days after a 3-dose regimen","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"183"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6","lowerLimit":"14.0","upperLimit":"19.7"},{"groupId":"OG001","value":"6.1","lowerLimit":"5.6","upperLimit":"6.6"}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serotype G3 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa Predose 1","description":"GMT of serotype G3 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa Predose 1","populationDescription":"Per Protocol Analysis","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"GMT","timeFrame":"Predose (Day 1 of a 3-dose regimen)","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"182"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","lowerLimit":"9.7","upperLimit":"13.6"},{"groupId":"OG001","value":"9.8","lowerLimit":"8.5","upperLimit":"11.3"}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serotype G3 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa 42 Days After a 3-dose Regimen","description":"GMT of serotype G3 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","populationDescription":"Per Protocol Analysis","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"GMT","timeFrame":"42 days after a 3-dose regimen","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"183"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","lowerLimit":"23.4","upperLimit":"33.5"},{"groupId":"OG001","value":"5.8","lowerLimit":"5.5","upperLimit":"6.3"}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serotype G4 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa Predose 1","description":"GMT of serotype G4 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa Predose 1","populationDescription":"Per Protocol Analysis","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"GMT","timeFrame":"Predose (Day 1 of a 3-dose regimen)","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"182"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","lowerLimit":"12.9","upperLimit":"18.6"},{"groupId":"OG001","value":"17.9","lowerLimit":"15.0","upperLimit":"21.3"}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serotype G4 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa 42 Days After a 3-dose Regimen","description":"GMT of serotype G4 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","populationDescription":"Per Protocol Analysis","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"GMT","timeFrame":"42 days after a 3-dose regimen","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"183"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.6","lowerLimit":"28.6","upperLimit":"39.6"},{"groupId":"OG001","value":"7.1","lowerLimit":"6.5","upperLimit":"7.7"}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serotype P1A in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa Predose 1","description":"GMT of serotype P1A in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa Predose 1","populationDescription":"Per Protocol Analysis","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"GMT","timeFrame":"Predose (Day 1 of a 3-dose regimen)","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"181"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.8","lowerLimit":"30.9","upperLimit":"44.0"},{"groupId":"OG001","value":"33.2","lowerLimit":"28.1","upperLimit":"39.3"}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serotype P1A in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa 42 Days After a 3-dose Regimen","description":"GMT of serotype P1A in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","populationDescription":"Per Protocol Analysis","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"GMT","timeFrame":"42 days after a 3-dose regimen","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"183"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.5","lowerLimit":"60.7","upperLimit":"91.3"},{"groupId":"OG001","value":"10.7","lowerLimit":"9.2","upperLimit":"12.4"}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serum Anti-rotavirus IgA in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa Predose 1","description":"GMT of serum anti-rotavirus IgA in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa Predose 1","populationDescription":"Per Protocol Analysis","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"GMT","timeFrame":"Predose (Day 1 of a 3-dose regimen)","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"181"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.1","upperLimit":"0.2"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.1","upperLimit":"0.2"}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serum Anti-rotavirus IgA in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa 42 Days After a 3-dose Regimen","description":"GMT of serum anti-rotavirus IgA in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","populationDescription":"Per Protocol Analysis","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"GMT","timeFrame":"42 days after a 3-dose regimen","groups":[{"id":"OG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart."},{"id":"OG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"183"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"160.0","lowerLimit":"119.0","upperLimit":"215.3"},{"groupId":"OG001","value":"0.2","lowerLimit":"0.1","upperLimit":"0.2"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"2","timeFrame":"Patients in this study were followed for all adverse experiences, for 14 days following each study vaccination.","description":"The number of patients listed in the Adverse Event tables is the number of patients who received study treatment.\n\nAlthough a patient may have had two or more clinical adverse experiences the patient is counted only once in a category. The same patient may appear in different categories.","eventGroups":[{"id":"EG000","title":"RotaTeq™ + INFANRIX Hexa","description":"Subjects in Group 1 received 3 concomitant doses of RotaTeq™ and INFANRIX™ hexa ≥28 to ≤42 days apart.","seriousNumAffected":3,"seriousNumAtRisk":201,"otherNumAffected":166,"otherNumAtRisk":201},{"id":"EG001","title":"Placebo + INFANRIX Hexa","description":"For subjects in Group 2, 3 concomitant doses of placebo were administered concomitantly with INFANRIX™ hexa at intervals of 4 to 6 weeks.","seriousNumAffected":6,"seriousNumAtRisk":202,"otherNumAffected":167,"otherNumAtRisk":202}],"seriousEvents":[{"term":"Abdominal symptom","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":201},{"groupId":"EG001","numAffected":1,"numAtRisk":202}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":201},{"groupId":"EG001","numAffected":1,"numAtRisk":202}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":201},{"groupId":"EG001","numAffected":1,"numAtRisk":202}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":201},{"groupId":"EG001","numAffected":2,"numAtRisk":202}]},{"term":"Gastroenteritis salmonella","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":201},{"groupId":"EG001","numAffected":1,"numAtRisk":202}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":201},{"groupId":"EG001","numAffected":1,"numAtRisk":202}]},{"term":"Accidental overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":201},{"groupId":"EG001","numAffected":1,"numAtRisk":202}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":201},{"groupId":"EG001","numAffected":1,"numAtRisk":202}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":201},{"groupId":"EG001","numAffected":0,"numAtRisk":202}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":201},{"groupId":"EG001","numAffected":1,"numAtRisk":202}]},{"term":"Crying","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":201},{"groupId":"EG001","numAffected":1,"numAtRisk":202}]},{"term":"Restlessness","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":201},{"groupId":"EG001","numAffected":1,"numAtRisk":202}]}],"otherEvents":[{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":201},{"groupId":"EG001","numAffected":3,"numAtRisk":202}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":201},{"groupId":"EG001","numAffected":8,"numAtRisk":202}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":57,"numAtRisk":201},{"groupId":"EG001","numAffected":65,"numAtRisk":202}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":201},{"groupId":"EG001","numAffected":28,"numAtRisk":202}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":201},{"groupId":"EG001","numAffected":5,"numAtRisk":202}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":62,"numAtRisk":201},{"groupId":"EG001","numAffected":48,"numAtRisk":202}]},{"term":"Irritability","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":201},{"groupId":"EG001","numAffected":4,"numAtRisk":202}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":201},{"groupId":"EG001","numAffected":2,"numAtRisk":202}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":106,"numAtRisk":201},{"groupId":"EG001","numAffected":114,"numAtRisk":202}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":201},{"groupId":"EG001","numAffected":6,"numAtRisk":202}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":201},{"groupId":"EG001","numAffected":5,"numAtRisk":202}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":201},{"groupId":"EG001","numAffected":3,"numAtRisk":202}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":201},{"groupId":"EG001","numAffected":17,"numAtRisk":202}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":201},{"groupId":"EG001","numAffected":5,"numAtRisk":202}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":201},{"groupId":"EG001","numAffected":2,"numAtRisk":202}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":201},{"groupId":"EG001","numAffected":4,"numAtRisk":202}]},{"term":"Crying","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":201},{"groupId":"EG001","numAffected":7,"numAtRisk":202}]},{"term":"Restlessness","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":201},{"groupId":"EG001","numAffected":16,"numAtRisk":202}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":201},{"groupId":"EG001","numAffected":11,"numAtRisk":202}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":201},{"groupId":"EG001","numAffected":1,"numAtRisk":202}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"Executive Vice President, Clinical and Quantitative Sciences","organization":"Merck Sharp & Dohme Corp","phone":"1-800-672-6372"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","removedCountries":["Austria","Belgium","Germany"]},"conditionBrowseModule":{"meshes":[{"id":"D012400","term":"Rotavirus Infections"}],"ancestors":[{"id":"D012088","term":"Reoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D007239","term":"Infections"}]},"interventionBrowseModule":{"meshes":[{"id":"D022243","term":"Rotavirus Vaccines"},{"id":"D000118","term":"Acetylglucosaminidase"}],"ancestors":[{"id":"D014765","term":"Viral Vaccines"},{"id":"D014612","term":"Vaccines"},{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"},{"id":"D001619","term":"beta-N-Acetylhexosaminidases"},{"id":"D006596","term":"Hexosaminidases"},{"id":"D006026","term":"Glycoside Hydrolases"},{"id":"D006867","term":"Hydrolases"},{"id":"D004798","term":"Enzymes"},{"id":"D045762","term":"Enzymes and Coenzymes"}]}},"hasResults":true}